US · GTBP · BIOTECHNOLOGY
GT Biopharma, Inc. (GTBP) intrinsic value and stock valuation
$2.96as of 2026-11-21 · Mkt cap 10.02M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
GT Biopharma, Inc. DCF and intrinsic value
InvestorsCraft values GTBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GTBP’s statements →
GT Biopharma, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-12.42M | -$-14.36M | -$-13.58M | -$-21.26M | -$-57.52M |
| Net income | -$-28.35M | -$-13.16M | -$-7.6M | -$-20.88M | -$-58.01M |
| EPSd | -$-5.15M | -$-6.93M | -$-5.63M | -$-655.16K | -$-2.06M |
| Operating cash flow | -$-12.91M | -$-12.9M | -$-8.85M | -$-15.22M | -$-15.61M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-12.91M | -$-12.9M | -$-8.85M | -$-15.22M | -$-15.61M |
| Total assets | $8.11M | $4.23M | $14.1M | $16.7M | $32.2M |
| Total debt | $0.00 | $0.00 | $60K | $170K | $30K |
| Net debt | -$-6.81M | -$-3.95M | -$-1.02M | -$-5.5M | -$-8.94M |
| Total equity | $5.79M | -$-1.67M | $7.48M | $11.7M | $21.9M |
| Cash and short-term investments | $6.81M | $3.95M | $14M | $16.5M | $32M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $3.47M | $5.8M | $6.47M | $8.81M | $9.59M |
| Selling, general and administrative expenses | $8.95M | $8.57M | $7.11M | $12.5M | $47.9M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $12.4M | $14.4M | $13.6M | $21.3M | $57.5M |
| Cost and expenses | $12.4M | $14.4M | $13.6M | $21.3M | $57.5M |
| Interest income | $120K | $400K | $780K | $290K | $40K |
| Interest expense | $130K | $0.00 | $210K | $10K | $720K |
| Depreciation and amortization | $0.00 | $0.00 | $13.6M | $0.00 | $0.00 |
| Ebitda | -$-28.23M | -$-13.16M | $5.98M | -$-20.96M | -$-57.48M |
| Operating income | -$-12.42M | -$-14.36M | -$-13.58M | -$-21.26M | -$-57.52M |
| Total other income/expenses, net | -$-15.93M | $1.2M | $5.98M | $370K | -$-500K |
| Income before tax | -$-28.35M | -$-13.16M | -$-7.6M | -$-20.88M | -$-58.01M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-28.35M | -$-13.16M | -$-7.6M | -$-20.88M | -$-58.01M |
| Weighted average shares outstanding | $5.51M | $1.9M | $1.35M | $31.9M | $28.2M |
| Weighted average diluted shares outstanding | $5.51M | $1.9M | $1.35M | $31.9M | $28.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.81M | $3.95M | $14M | $16.5M | $32M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $8.11M | $4.23M | $14.1M | $16.6M | $32.2M |
| Property, plant and equipment, net | $0.00 | $0.00 | $50K | $170K | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $0.00 | $0.00 | $50K | $170K | $0.00 |
| Total assets | $8.11M | $4.23M | $14.1M | $16.7M | $32.2M |
| Accounts payable | $750K | $3.85M | $4.33M | $3.14M | $8.19M |
| Short-term debt | $0.00 | $0.00 | $60K | $110K | $30K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.9M |
| Total current liabilities | $2.32M | $5.9M | $6.63M | $4.94M | $10.3M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $60K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $0.00 | $0.00 | $60K | $0.00 |
| Capital lease obligations | $0.00 | $0.00 | $60K | $170K | $0.00 |
| Total liabilities | $2.32M | $5.9M | $6.63M | $5M | $10.3M |
| Common stock | $30K | $0.00 | $0.00 | $30K | $1.15M |
| Retained earnings | -$-723.9M | -$-695.23M | -$-682.07M | -$-674.47M | -$-653.58M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $1.11M |
| Total equity | $5.79M | -$-1.67M | $7.48M | $11.7M | $21.9M |
| Total investments | $0.00 | $0.00 | $12.9M | $10.8M | $23M |
| Total debt | $0.00 | $0.00 | $60K | $170K | $30K |
| Net debt | -$-6.81M | -$-3.95M | -$-1.02M | -$-5.5M | -$-8.94M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-28.35M | -$-13.16M | -$-7.6M | -$-20.88M | -$-58.01M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $430K | $230K | $2.2M | $7.65M | $33.9M |
| Change in working capital | -$-920K | $830K | $1.82M | -$-1.99M | $7.94M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.3M | $940K | $1.96M | -$-2.03M | $7.08M |
| Net cash provided by operating activities | -$-12.91M | -$-12.9M | -$-8.85M | -$-15.22M | -$-15.61M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | $12.9M | -$-2.01M | $12.1M | -$-23.04M |
| Common stock issued | $16M | $2.98M | $6.27M | $0.00 | $24.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | -$-220K | $0.00 |
| Dividends paid | -$-230K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $15.8M | $2.98M | $6.27M | -$-220K | $42.3M |
| Net change in cash | $2.86M | $2.96M | -$-4.59M | -$-3.3M | $3.67M |
| Cash at end of period | $6.91M | $4.04M | $1.08M | $5.67M | $8.97M |
| Operating cash flow | -$-12.91M | -$-12.9M | -$-8.85M | -$-15.22M | -$-15.61M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-12.91M | -$-12.9M | -$-8.85M | -$-15.22M | -$-15.61M |
Line items
Line items
Line items
About GT Biopharma, Inc.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
- CEO
- Michael Martin Breen
- Employees
- 1
- Beta
- 0.84
Explore
Frequently asked questions
What is the intrinsic value of GT Biopharma, Inc. (GTBP)?
InvestorsCraft does not currently publish an intrinsic value for GTBP. How the IC value is calculated.
Is GTBP undervalued?
InvestorsCraft does not publish an undervaluation signal for GTBP at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.